Latest news with #Syfovre
Yahoo
09-05-2025
- Business
- Yahoo
Apellis price target lowered to $20 from $28 at Scotiabank
Scotiabank analyst Greg Harrison lowered the firm's price target on Apellis (APLS) to $20 from $28 and keeps a Sector Perform rating on the shares. The company had a weak Q1, with Syfovre revenues in geographic atrophy missing expectations due to underfunding of retinal therapeutics co-pay assistance programs and inventory draw down, the analyst tells investors. The firm is lowering its price target on the stock to reflect its updated expectations for Syfovre sales. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on APLS: Disclaimer & DisclosureReport an Issue Apellis price target lowered to $47 from $55 at Baird Apellis price target lowered to $26 from $30 at Wells Fargo Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks Hold Rating on Apellis Pharmaceuticals Amid Revenue Uncertainty and Competitive Pressures Apellis Pharmaceuticals Reports Q1 2025 Financial Results Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
Why Apellis Pharmaceuticals Wilted on Wednesday
The company unveiled its first-quarter results. Unfortunately, it missed analyst estimates on both the top and bottom lines. 10 stocks we like better than Apellis Pharmaceuticals › A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (NASDAQ: APLS) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 (SNPINDEX: ^GSPC) closed in the black with a 0.4% gain. In its first quarter, Apellis booked revenue of $166.8 million, the bulk of which comprised slightly under $150 million in U.S. product sales. That total represented a decline of 3% year over year. Of the company's drugs, Syfovre was the top seller, bringing in revenue of over $130 million, while Empaveli was the runner-up with nearly $20 million. With higher costs during the quarter, Apellis's net loss deepened. It came in at over $92 million ($0.74 per share) under generally accepted accounting principles (GAAP) standards, against the $86 million in the same period last year. The company was also negatively affected by outside factors. In its earnings release, it quoted CEO Cedric Francois as explaining that "revenue was impacted by funding shortages at third-party co-pay assistance programs and a larger-than-expected drawdown of total channel inventory, including physician offices." Regardless, Apellis missed on both the top and bottom lines. Analysts were collectively modeling slightly under $198 million for total revenue, and a net loss of only $0.34 per share. It was certainly a quarter to forget for Apellis, but I don't feel investors should give up hope on the stock. It continues to develop both Syfovre and Empaveli for new indications, saying in the earnings release that the latter is making good progress toward eventual Food and Drug Administration (FDA) approval for kidney disorders C3 glomerulopathy (C3G) and complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN). Apellis added that a decision from the regulator is expected in July. Before you buy stock in Apellis Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apellis Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,546!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $695,897!* Now, it's worth noting Stock Advisor's total average return is 893% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Apellis Pharmaceuticals Wilted on Wednesday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
29-04-2025
- Business
- Associated Press
Tavo Biotherapeutics Announces Appointment of Seasoned Executives to Key Posts
---- Lukas Scheibler, Ph.D. to become Chief Research and Development Officer and Graham Cooper to become Chief Financial Officer ---- Additions to senior team will drive Tavo's strategy to develop new innovative therapeutics addressing critical unmet needs in glaucoma and retinal disease IRVINE, Calif. , April 29, 2025 /PRNewswire/ -- Tavo Biotherapeutics, a leading innovator in the ophthalmology industry, today announced the appointment of Lukas Scheibler, Ph.D. as Chief Research and Development Officer, and Graham Cooper as Chief Financial Officer. Both bring proven track records of success in the biotechnology industry. 'I am thrilled to bring on Lukas and Graham to Tavo's senior team,' said Gary Berman, Chief Executive Officer. 'Lukas has had an illustrious career in ophthalmology, from introducing Lucentis in Europe for Novartis, running clinical development at Alcon, and pioneering the development of Syfovre for geographic atrophy at Apellis. He is a recognized leader in the industry, and he will play a central role in driving our clinical and pre-clinical programs in treatments for glaucoma and retinal disease.' Berman continued, 'Likewise, Graham has extensive experience in the biotech field, across multiple therapeutic indications. Throughout his career he has raised over a billion dollars in capital, having taken companies public and scaled enterprises from the early stages, hiring teams and managing growth. He is a recognized leader in the venture capital and public investor communities and brings a wealth of experience and strong relationships to Tavo. Lukas and Graham fill pivotal roles for Tavo, and they join us at a key time as we prepare to raise capital and advance our pipeline into the clinic. Attracting these accomplished executives builds on our momentum in developing breakthrough therapies that address fundamental unmet needs in ophthalmology.' Dr. Lukas Scheibler was most recently Chief Innovation Officer at Apellis. In this role, he was responsible for all research and development activities through human proof of concept. Prior to that, he was Head of Clinical Development at Alcon, where he was responsible for the planning and execution of all clinical trials. Dr. Scheibler began his career in ophthalmology in research and development at Novartis, where he played a key role in the in-licensing and approval of Lucentis in Europe. He holds a Ph.D. from the University of Lausanne, Switzerland, and completed postdoctoral training at Harvard Medical School. Graham Cooper was Chief Financial Officer for Receptos, which he joined prior to its IPO. At Receptos, he played a key role in managing through a dramatic growth phase and raising capital, culminating in its sale to Celgene for $7.8 billion. He also served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, developing innovative anti-viral therapies for the treatment of HBV, as well as other private and public biotechnology companies. Prior to his operating roles, Mr. Cooper held positions of increasing responsibility at Deutsche Bank Securities, including Director, Health Care Investment Banking. He began his career at Deloitte & Touche and was previously a CPA. Mr. Cooper currently serves as a member of the board of Beam Therapeutics (BEAM) and chairman of the board of Kezar Life Sciences (KZR). Mr. Cooper received a BA in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business. About Tavo Biotherapeutics Tavo Biotherapeutics is developing innovative new treatments to address critical unmet needs in ophthalmology. TAV-001 is being developed for the treatment of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown substantial reduction in intraocular pressure, as well as signals of neuroprotection, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic macular edema and diabetic retinopathy, as well as both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program. Media Contact: Graham Cooper Chief Financial Officer [email protected] View original content: SOURCE Tavo Biotherapeutics
Yahoo
05-03-2025
- Business
- Yahoo
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million. JP Morgan maintains the Overweight rating with a price forecast of $54. Analyst Anupam Rama says Apellis' lead asset, pegcetacoplan (Syfovre/Empaveli), represents a differentiated asset in the complement space, with opportunities across ophthalmology, hematology, neurology, and nephrology indications. Also Read: The company generated Syfovre sales of $167.8 million and $611.9 million for the fourth quarter and full year 2024, respectively. Delivered approximately 94,000 Syfovre doses to physician practices in the fourth quarter, including approximately 89,000 commercial vials and 4,600 samples. More than 510,000 Syfovre injections, including clinical trials, are estimated to have been administered since launch through December 2024. JP Morgan views Syfovre as an over $1.5 billion peak potential drug, even with conservative assumptions. 'Overall, physicians continue to use the product, driving growth, and we anticipate a fundamental and sentiment shift driving upside in APLS shares,' the analyst writes. Analyst Rama also expects that the Empaveli C3 glomerulopathy and primary immune complex glomerulonephritis (C3G/IC-MPGN) opportunity will be a driver for Apellis stock. The company has submitted a supplemental marketing application for approval of Empaveli based on Phase 3 VALIANT results at six months; if approved, a U.S. launch is expected in 2H 2025. Price Action: APLS stock is up 3.27% at $25.87 at the last check Wednesday. Read Next:Date Firm Action From To Mar 2022 Goldman Sachs Maintains Buy Mar 2022 Raymond James Maintains Strong Buy Jan 2022 Raymond James Maintains Strong Buy View More Analyst Ratings for APLS View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APELLIS PHARMACEUTICALS (APLS): Free Stock Analysis Report This article Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
